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Table. Outcomes after CEA
Variable
30-day 5-year
Overall (n¼ 231) Group 1 (n ¼ 58) Group 2 (n ¼ 173)
P
Overall Group 1 Group 2
PNo. (%) No. (%) No. (%) (%) (%) (%)
Stroke + death 6 (2.6) 4 (6.9) 2 (1.2) .29 24 37 20 .07
Death 1 (0.4) 0 (0) 1 (0.6) .81 20 29 18 .57
Stroke 5 (2.2) 4 (6.9) 1 (0.6) .07 7.0 11 5.5 .03
MI 4 (1.7) 0 (0) 4 (2.3) .24 1.8 0 2.4 .24
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Volume 59, Number 6S Abstracts 63Sartery stenosis (CAS) were reviewed. In group 1 symp-
toms (minor stroke, transient ischemic attack, TIA)
occurred #14 days; and in group 2 symptoms occurred
>14 days before CEA. Primary end points were com-
bined stroke and death; secondary end points were
stroke, death, and myocardial infarction (MI).
Results: A total of 231 CEAs were performed in 226
symptomatic patients (32% female; mean age, 72 6 8.7
years), comprising 58 (25%) in group 1 and 173 (75%) in
group 2. Sixty patients (26%) presented with stroke
(group1, 19%; group 2, 28%; P ¼ .16). The 30-day stroke
and death rate was 2.6% and not signiﬁcantly different be-
tween groups (Table). Three of four early strokes in group
1 occurred in patients with repeated transient ischemic at-
tacks #2 days before CEA. Mean follow-up was 3.9 years
(range, 30 days-10.8 years). The Table presents 5-year out-
comes. In multivariable analysis, patients with symptoms
#14 days tended to have increased rate of stroke.
Conclusions: CEA can be performed in symptomatic
patients with a 30-day stroke and death rate of 2.6%, but
there was a trend to increased rate of stroke if the opera-
tion was performed #14 days after onset of symptoms. Pa-
tients with repeated transient ischemic attacks, operated
on #2 days, had the highest risk of stroke. For this select
group of symptomatic patients, outcomes quoted based on
prospective randomized trials may not apply.
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Risk Factors for Suboptimal Medical Therapy in
Patients Undergoing Revascularization for
Symptomatic Peripheral Arterial Disease: A Vascular
Study Group of Greater New York Initiative
Andrew J. Meltzer, Art Sedrakyan, Abby Isaacs, Ellen C.
Meltzer, Peter H. Connolly, Darren B. Schneider. Vascular
Surgery, Weill Cornell Medical College, New York, NY
Objectives: The objective of this study is to identify
risk factors for suboptimal medical therapy among patients
undergoing surgical bypass and percutaneous interventions
for symptomatic peripheral arterial disease (PAD).Methods: The Vascular Study Group of Greater
New York (VSGGNY) database was used to identify all
patients undergoing percutaneous therapy or surgical
bypass for PAD (2011-2013). Bivariate analyses were
performed to identify factors associated with preoperative
statin use and antiplatelet therapy. Multivariate relative
risk regression models were developed to identify pa-
tients at risk for suboptimal medical therapy.
Results: A total of 1030 patients underwent endo-
vascular therapy (n ¼ 822 [80%]) or surgical bypass
(n ¼ 208 [20%]) for symptomatic peripheral arterial dis-
ease (57.2% claudication, 15% rest pain, 27.8% tissue
loss). Preoperative statin use was observed in 59%. An-
tiplatelet therapy was observed in 79% of patients.
Bivariate analysis revealed reduced statin use among pa-
tients without other cardiovascular risk factors such as
hypertension (63% vs 39.3%; P < .0001) and coronary
artery disease (CAD) with prior cardiac revasculariza-
tion (coronary artery bypass grafting [CABG]/percuta-
neous coronary intervention [PCI]; 75.2% vs 47.4%; P
< .0001). Multivariate relative risk regression conﬁrmed
increased statin use among patients with other cardio-
vascular risk factors including hypertension (1.14
[1.02-1.27]; P ¼ .02), and CAD with prior CABG/
PCI (1.22 [1.13-1.31]; P < .0001). There was a clear
trend towards reduced statin use in patients aged >80
(0.92 [0.84-0.1.0]; P ¼ .059). By multivariate regres-
sion, antiplatelet therapy use was associated with CAD
and prior CABG/PCI (1.11 [1.04-1.17]; P ¼ .0015)
and prior peripheral revascularization (1.07 [1.01-
1.13]; P ¼ .03).
Conclusions: Patients with symptomatic PAD, but
without an antecedent cardiovascular history, are less likely
to be optimally managed with statins and antiplatelet ther-
apy preoperatively and should be actively targeted for med-
ical optimization by vascular specialists.
Author Disclosures: P. H. Connolly: Nothing to
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64S Abstracts June Supplement 2014Objectives: The aim of this study was to evaluate the
impact of smoking cessation on the progression of throm-
boangiitis obliterans (Buerger’s disease). The impact of
various comorbidities on limb amputation was also
evaluated.
Methods: A retrospective analysis of the cross-
sectional National Inpatient Sample (2000-2011) was
used to identify patients with a diagnosis of Buerger’s
disease (International Classiﬁcation of Diseases, Ninth
Revision, 44.31). Patients who underwent extremity
amputation were characterized according to smoking
status and comorbidities, including renal failure, diabetes,
coagulopathy, hypertension, heart disease, and chronic
obstructive pulmonary disease, and compared with
those who did not undergo amputation. Odds ratios
were calculated for all statistically signiﬁcant (P < .05) dif-
ferences identiﬁed using the Fisher exact test and Student
t-test.
Results: A total of 4,489 patients with Buerger’s
disease were identiﬁed in the United States between
2000 and 2011, of which 193 (4.3%) underwent limb
amputation. A total of 1908 (42.5%) patients were
smokers. Smoking was slightly more common among
patients who underwent amputation (46.1% vs 42.3%;
P ¼ .30; 95% conﬁdence interval, e0.11 to 0.03). Of
the comorbidities evaluated, renal failure was two times
more common among patients who underwent amputa-
tion (6.2% vs 3.2%; OR, 2; P ¼ .02; 95% conﬁdence
interval, e0.06 to e0.004). Patients who were former
smokers were just as likely to require limb amputation
(9.3% vs 11.5%; P ¼ .35).
Conclusions: Although the association between
smoking and Buerger’s disease is well understood,
whether smoking leads to the limb amputation from
this disease is unclear. This study demonstrates that the
primary factor associated with limb amputation
from Buerger’s disease is end-stage renal disease, not
smoking. Further, smoking cessation does not appear to
prevent progression to limb amputation in Buerger’s
disease.
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Vascular Surgeons Can Improve the Cardiovascular
Health of Patients With Clinical Atherosclerotic
Cardiovascular Disease by Implementing an Intensive
Lipid-Lowering Regimen and Providing Smoke
Cessation Counseling
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Objectives: To assess the impact of a vascular surgery-
led program to improve the cardiovascular risk of patients
with clinical atherosclerotic cardiovascular disease
(ASCVD) by implementing an intensive lipid-lowering
regimen and providing smoke cessation counseling.
Methods: The records of all patients seen in a single-
center vascular surgery clinic over a 1-month period inNovember 2013 were retrospectively reviewed till October
1, 2011, when the vascular surgery service implemented a
cardiovascular risk reduction program in patients with clin-
ical ASCVD.
Results: Included were 144 consecutive patients with
a median follow-up of 315 days (range, 0-740 days). Pre-
intervention, the baseline median low-density lipoprotein
(LDL) was 86 mg/dL (range, 39-197 mg/dL) and 96 pa-
tients (71.1%) had an LDL >70 mg/dL. Fifty-two patients
(37%) were current smokers, 41 (71%) smoked heavily
(more than one pack per day). Fifty-ﬁve percent of patients
had documentation that this intervention was administered
at the initial vascular surgery encounter after this program
was started. The mean lag time to the ﬁrst vascular surgery
encounter with intervention documentation was 117 days
(median, 0 days; range 0-721 days). At the latest follow-
up, 92 (72%) of the encounters by a vascular surgeon docu-
mented that the intervention was administered, ﬁnal
median LDL was 79 mg/dL (range, 31-198 mg/dL), 80
patients (62%) had an LDL >70 mg/dL, and 60 patients
(47.2%) had a decrease in their LDL. Patients that had
no observed decrease in their LDL had a signiﬁcantly lower
mean level at baseline (82.3; standard deviation, 28.7;
range 39-197 mg/dL) compared with those with an
observed decrease in LDL (mean, 98.8; standard deviation,
32.8; range, 42-187 mg/dL; P ¼ .003). At the latest
follow-up, 41 patients (31.5%) were currently smoking,
21 (43.7%) of whom smoked heavily (more than one
pack per day).
Conclusions: Vascular surgeons can improve the car-
diovascular health of their patients by implementing a pro-
gram of intensive lipid control and smoking cessation in
patients with clinical ASCVD. Further studies are needed
to determine the impact on cardiovascular event rates.
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Objectives: The academic mission is under strain.
Although clinical activity is easily quantiﬁed by the Relative
Value Units (RVU), there are multiple ad hoc measures of
academic activity. This study reports the use of academic
RVU (aRVU) derived for all nonclinical activities to justify
nonclinical protected time of individual faculty, prioritize
divisional activities, and drive the academic.
Methods: All nonclinical activity for divisional faculty
were correlated and subjected to a deﬁned scoring sys-
tem. The system was set up in ﬁve modules (publica-
tions, presentation, clinical trial, grants educational,
administration and community). Each module was
